{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:06:40Z","timestamp":1792624000571,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104869","type":"journal-article","created":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T09:27:08Z","timestamp":1688290028000},"page":"104869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Assessing the utility of magnetic resonance imaging-based \u201cSuStaIn\u201d disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-4526","authenticated-orcid":false,"given":"Xiaotong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Caba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibeshih","family":"Belachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie R","family":"Gafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2023.104869_bib0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. B"},{"key":"10.1016\/j.msard.2023.104869_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.msard.2018.12.007","article-title":"Multiple sclerosis risk factors contribute to onset heterogeneity","volume":"28","author":"Briggs","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10076","key":"10.1016\/j.msard.2023.104869_bib0003","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","article-title":"Diagnosis of multiple sclerosis: progress and challenges","volume":"389","author":"Brownlee","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.msard.2023.104869_bib0004","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104869_bib0005","doi-asserted-by":"crossref","first-page":"11093","DOI":"10.1109\/ACCESS.2019.2891970","article-title":"Semi supervised learning with deep embedded clustering for image classification and segmentation","volume":"7","author":"Enguehard","year":"2019","journal-title":"IEEE Access"},{"issue":"1","key":"10.1016\/j.msard.2023.104869_bib0006","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/s41467-021-23538-6","article-title":"Author correction: identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data","volume":"12","author":"Eshaghi","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.msard.2023.104869_bib0007","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/s41467-021-22265-2","article-title":"Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data","volume":"12","author":"Eshaghi","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.msard.2023.104869_bib0008","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.neuroimage.2012.01.062","article-title":"An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease","volume":"60","author":"Fonteijn","year":"2012","journal-title":"Neuroimage"},{"issue":"12","key":"10.1016\/j.msard.2023.104869_bib0009","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"suppl 2","key":"10.1016\/j.msard.2023.104869_bib0010","first-page":"404","article-title":"P426. associations of disease severity and outcomes with MRI based \u2018SuStaIn\u2019 disease subtypes in secondary progressive MS","volume":"27","author":"Gafson","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2023.104869_bib0011","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104869_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104337","article-title":"Current review and next steps for artificial intelligence in multiple sclerosis risk research","volume":"132","author":"Hartmann","year":"2021","journal-title":"Comput. Biol. Med."},{"issue":"5","key":"10.1016\/j.msard.2023.104869_bib0013","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104869_bib0014","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2023.104869_bib0015","article-title":"Clinical course of multiple sclerosis. cold spring harb","volume":"8","author":"Klineova","year":"2018","journal-title":"Perspect. Med."},{"issue":"11","key":"10.1016\/j.msard.2023.104869_bib0016","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3174\/ajnr.A7274","article-title":"A combined radiomics and machine learning approach to overcome the clinicoradiologic paradox in multiple sclerosis","volume":"42","author":"Pontillo","year":"2021","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"9","key":"10.1016\/j.msard.2023.104869_bib0017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/metabo10090366","article-title":"Lipidomic UPLC-MS\/MS profiles of normal-appearing white matter differentiate primary and secondary progressive multiple sclerosis","volume":"10","author":"Pousinis","year":"2020","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.msard.2023.104869_bib0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756285613484079","article-title":"Magnetic resonance monitoring of lesion evolution in multiple sclerosis","volume":"6","author":"Rovira","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104869_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117451","article-title":"Estimation of multiple sclerosis lesion age on magnetic resonance imaging","volume":"225","author":"Sweeney","year":"2021","journal-title":"Neuroimage"},{"issue":"8","key":"10.1016\/j.msard.2023.104869_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104869_bib0021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ana.21640","article-title":"The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?","volume":"65","author":"Weiner","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104869_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2021.613261","article-title":"Ordinal SuStaIn: subtype and stage inference for clinical scores, visual ratings, and other ordinal data","volume":"4","author":"Young","year":"2021","journal-title":"Front. Artif. Intell."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300370X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300370X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:09:44Z","timestamp":1737623384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482300370X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":22,"alternative-id":["S221103482300370X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104869","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the utility of magnetic resonance imaging-based \u201cSuStaIn\u201d disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104869"}}